References
Benjamini, Y. & Hochberg, Y. (1995) Controlling the false discovery rate: A practical and powerful approach to multiple testing.Journal of the Royal Statistical Society B, 57 , 289-300
Baandrup Kristiansen, M. N. , Veidal, S. S., Christoffersen, C., Feigh, M., Vrang, N., Roth, J. D., …, Jelsing, J. (2019) Validity of biopsy-based drug effects in a diet-induced obese mouse model of biopsy-confirmed NASH. BMC Gastroenterology, 19 , 228
Chalasani, N., Younossi, Z., Lavine, J. E., Charlton, M., Cusi, K., Rinella, M., …, Sanyal, A.J. (2018) The diagnosis and management of nonalcoholic fatty liver disease: Practice guidance from the American Association for the Study of Liver Diseases. Hepatology,67, 328-357
Clapper, J. R., Hendricks, M. D., Gu, G., Wittmer, C., Dolman, C. S., Herich, J., …, Roth, J. D. (2013) Diet-induced mouse model of fatty liver disease and nonalcoholic steatohepatitis reflecting clinical disease progression and methods of assessment. American Journal of Physiology - Gastrointestinal and Liver Physiology , 305 , G483-95
Costa-Silva, J., Domingues, D., & Lopes, F.M. (2017) RNA-Seq differential expression analysis: An extended review and a software tool. PLoS One , 12 , e0190152.
Diehl, A.M., & Day, C. (2017) Cause, Pathogenesis, and treatment of nonalcoholic steatohepatitis. New England Journal of Medicine,377 , 2063-2072
Dulai, P.S., Singh, S., Patel, J., Soni, M., Prokop, L. J., Younossi, Z., …, Loomba, R. (2017) Increased risk of mortality by fibrosis stage in nonalcoholic fatty liver disease: Systematic review and meta-analysis. Hepatology, 65 , 1557-1565
Ekstedt, M., Hagström, H., Nasr, P., Fredrikson, M., Stal, P., Kechagias, S., & Hultcrantz, R. (2015) Fibrosis stage is the strongest predictor for disease-specific mortality in NAFLD after up to 33 years of follow-up. Hepatology, 61 , 1547–1554
Erion, M. D., Cable, E. E., Ito, B. R., Jiang, H., Fujitaki, J. M., Finn, P. D., …, Linemeyer, D. L. (2007) Targeting thyroid hormone receptor‐beta agonists to the liver reduces cholesterol and triglycerides and improves the therapeutic index. Proceedings of the National Academy of Sciences of the United States of America,104 :15490‐15495
Estes, C., Anstee, Q. M., Arias-Loste, M. T., Bantel, H., Bellentani, S., Caballeria, J.,…,Razavi, H. (2018) Modeling NAFLD disease burden in China, France, Germany, Italy, Japan, Spain, United Kingdom, and United States for the period 2016-2030. Journal of Hepatology, 69 , 896-904
Estes, C., Razavi, H., Loomba, R., Younossi, Z., & Sanyal, A.J. (2018) Modeling the epidemic of nonalcoholic fatty liver disease demonstrates an exponential increase in burden of disease. Hepatology,67 , 123-133
Garber, K. (2019) The new liver epidemic. Nature Biotechnology,37 , 209-214
Carrasco-Torres, G., Fattel-Fazenda, S., López-Alvarez, G. S., García-Román, R., Villa-Treviño, S., Vásquez-Garzón, V. R. (2016) The transmembrane transporter ABCC3 participates in liver cancer progression and is a potential biomarker. Tumour Biology, 37 , 2007-2014
Hansen, H. H., Feigh, M., Veidal S. S., Rigbolt, K. T., Vrang, N., & Fosgerau, K. Mouse models of nonalcoholic steatohepatitis in preclinical drug development. Drug Discovery Today , 22 , 1707-1718
Harrison, S.A., Bashir, M.R., Guy, C.D., Zhou, R., Moylan, C.A., Frias, J.P., …, Moussa, S. E. (2019) Resmetirom (MGL-3196) for the treatment of non-alcoholic steatohepatitis: a multicentre, randomised, double-blind, placebo-controlled, phase 2 trial. The Lancet,394 , 2012-2024.
Kelly, M. J., Pietranico‐Cole, S., Larigan, J. D., Haynes, N. E., Reynolds, C. H., Scott, N., …, Tilley J. (2014) Discovery of 2‐[3,5‐dichloro‐4‐(5‐ isopropyl‐6‐oxo‐1,6‐dihydropyridazin‐3‐yloxy)phenyl]‐3,5‐dio xo‐2,3,4,5‐ tetrahydro[1,2,4]triazine‐6‐carbonitrile (MGL‐3196), a Highly Selective Thyroid Hormone Receptor beta agonist in clinical trials for the treatment of dyslipidemia. Journal of Medicinal Chemistry 57 , 3912‐3923.
Kleiner, D.E., Brunt, E.M., Van Natta, M., Behling, C., Contos, M.J., Cummings, O.W., …, Sanyal, A. J. (2005) Design and validation of a histological scoring system for nonalcoholic fatty liver disease.Hepatology, 41 , 1313-1321
Krämer, A., Green, J., Pollard, J. Jr, & Tugendreich, S. (2014) Causal analysis approaches in Ingenuity Pathway Analysis.Bioinformatics, 30 , 523-530.
Krause, C., Grohs, M., El Gammal, A. T., Wolter, S., Lehnert, H., Mann, O., Mittag, J., & Kirchner, H. (2018) Reduced expression of thyroid hormone receptor β in human nonalcoholic steatohepatitis.Endocrine Connections 7 , 1448-1456
Kristiansen, M. N., Veidal, S. S., Rigbolt, K. T., Tølbøl, K. S., Roth, J. D., Jelsing, J., Vrang, N., & Feigh, M. (2016) Obese diet-induced mouse models of nonalcoholic steatohepatitis-tracking disease by liver biopsy. World Journal of Hepatology , 8 , 673-84
Martagon, A. J., Lin, J. Z., Cimini, S. L., Webb, P., & Phillips, K. J. (2015) The amelioration of hepatic steatosis by thyroid hormone receptor agonists is insufficient to restore insulin sensitivity in ob/ob mice.PLoS One 10 , e0122987
Nien, H. C., Sheu, J. C., Chi, Y. C., Chen, C. L., Kao, J. H., & Yang, W. S. (2018) One-year weight management lowers lipopolysaccharide-binding protein and its implication in metainflammation and liver fibrosis. PLoS One 13 , e0207882
Perra, A., Simbula, G., Simbula, M., Pibiri, M., Kowalik, M. A., Sulas, P., …, Columbano, A. (2008) Thyroid hormone (T3) and TRβ agonist GC-1 inhibit/reverse nonalcoholic fatty liver in rats. The FASEB Journal 22 , 2981-2989
Sinha, R. A., Bruistroop, E., Singh, B. K., & Yen, P. M. (2019) Nonalcoholic Fatty Liver Disease and Hypercholesterolemia: Roles of Thyroid Hormones, Metabolites, and Agonists. Thyroid,29 , 1173-1191
Thompson, K. J., Austin, R. G., Nazari, S. S., Gersin, K. S., Iannitti, D. A., McKillop, I. H. (2018) Altered fatty acid-binding protein 4 (FABP4) expression and function in human and animal models of hepatocellular carcinoma. Liver International 38 , 1074-1083
Vatner, D. F., Weismann, D., Beddow, S. A., Kumashiro, N., Erion, D. M., Liao, X. H., …, Samuel, V. T. (2013) Thyroid hormone receptor-β agonists prevent hepatic steatosis in fat-fed rats but impair insulin sensitivity via discrete pathways. American Journal of Physiology - Endocrinology and Metabolism 305 , E89-100
Younossi, Z. M., Koenig, A. B., Abdelatif, D., Fazel, Y., Henry, L., & Wymer, M. (2016) Global epidemiology of nonalcoholic fatty liver disease-Meta-analytic assessment of prevalence, incidence, and outcomes.Hepatology, 64 , 73–84